Skip to main content
. Author manuscript; available in PMC: 2016 Sep 1.
Published in final edited form as: J Hepatol. 2015 Apr 20;63(3):670–678. doi: 10.1016/j.jhep.2015.04.013

Figure 5. Gas6 and sAxl serum levels are increased in alcoholic liver disease (ALD) and HCV-infected patients.

Figure 5

A, Gas6 and B, Axl serum levels were measured in control individuals and patients with liver disease associated to alcohol consumption. Groups: C, control, F, Initial liver fibrosis (F0/F1), CH, hepatic cirrhosis, and DCH, decompensated hepatic cirrhosis. Additional data of patients is provided in Table 1. *, P≤0.05, **, P≤0.001 between groups. 1-way ANOVA, Newman-Keuls Multiple Comparison Test. C, Correlation analysis between Gas6/sAxl and MELD score was calculated for all the ALD patients (n=30). D, sAG index, an algorithm calculated by multiplication of sAxl and Gas6 concentrations is plotted against MELD index. E, Gas6 and F, Axl serum levels were measured in HCV patients with different fibrosis staging. Groups: F0 (no fibrosis), F1 (mild), F2 (moderate), and F3/F4 (severe fibrosis/cirrhosis). *, P≤0.05, **, P≤0.01 between groups. 1-way ANOVA, Newman-Keuls Multiple Comparison Test.